This activity is sponsored by

This activity is supported by an educational grant from

Michael Pfreundschuh, MD – Presenter
Director, Department of Internal Medicine
Professor of Internal Medicine
Saarland University Medical School
Saarbrucken, Germany

Anas Younes, MD – Content Reviewer
Professor of Medicine, Department of Lymphoma/Myeloma
MD Anderson Cancer Center
Chairman, Executive Committee of the Medical Staff
University of Texas
Houston, Texas

STATEMENT OF NEED
For the first time in years, several advances have been made in the management of B-cell malignancies, including improved survival as a result of the integration of monoclonal antibodies and the introduction of novel therapies. Despite these improvements, several issues remain. Where do the available therapies for B-cell malignancies fit within the context of currently accepted treatment standards? How should novel therapies for B-cell malignancies be integrated? What about sequencing? Can novel therapies be used in combination regimens? What are the most rational combination regimens for B-cell malignancies? What side effects can be expected from these novel therapy combinations? It is well-noted that Canada and European countries are able to accrue participants for clinical trials faster than the United States for a myriad of reasons, and significant data regarding the treatment of hematologic malignancies has been derived from large phase III clinical trials conducted in Europe and Canada. Clinical results from European and Canadian trials are continually highlighted in the published literature and national/international meetings. US-based practitioners, charged with the care of patients with B-cell malignancies, must have in-depth knowledge of current preclinical and clinical data in order to make the most appropriate treatment-related decisions for his/her patients with a B-cell malignancy and must understand the placement of said data in the context of the American patient.

LEARNING OBJECTIVES
Upon completion of this educational program, participants should be better able to:

• Describe the importance of diagnostic and pathologic evaluation of B-cell malignancies
• Understand the rationale for the development and integration of treatment strategies in B-cell malignancies
• Examine clinical trial results of treatment regimens, both containing novel agents and combinations, in patients with B-cell malignancies

TARGET AUDIENCE
This educational initiative is designed for hematologists, hematologist-oncologists, and allied healthcare professionals caring for patients with hematologic malignancies.

ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION
	Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Educational Concepts Group, LLC designates this continuing education activity for 1.0 contact hour (0.10 CEUs). (UAN 0199-0000-09-014-H01-P).

TYPE OF ACTIVITY: Application-based

METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period October 7, 2009 through October 6, 2010, participants must
1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test. Participants must view each section in its entirety
to receive full credit for this program.

CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit certificates via the website, www.educationalconcepts.net.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by an educational grant from Cephalon Oncology.

ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS:
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.

FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.

The following faculty members have declared relevant financial relationships:

CME/CE INQUIRIES
For further information, please contact: Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681
Fax: 1.770.933.1692
www.educationalconcepts.net

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.